SR0119LRB103 31105 LAW 57766 r


  
1
SENATE RESOLUTION

  
 
2    WHEREAS, Many people with serious mental health 
3conditions, such as bipolar disorder, major depression, 
4schizophrenia, and schizoaffective disorder, or 
5gastrointestinal disorders, including gastroparesis, nausea, 
6and vomiting, may be treated with medications that work as 
7dopamine receptor blocking agents (DRBAs), including 
8antipsychotics; and
  
 
9    WHEREAS, While ongoing treatment with these medications 
10can be necessary, prolonged use can also lead to tardive 
11dyskinesia (TD), an involuntary movement disorder that is 
12characterized by uncontrollable, abnormal, and repetitive 
13movements of the face, torso, and/or other body parts; and
  
 
14    WHEREAS, It is estimated that TD affects approximately 
15600,000 people in the United States, and approximately 70% of 
16people with TD have not been diagnosed, making it important to 
17raise awareness about the symptoms and impact of TD because 
18even mild symptoms of TD can have physical, social, and 
19emotional consequences; and
  
 
20    WHEREAS, It is important for  people taking DRBA medication 
21to be monitored for TD; regular screening for TD in these 
22patients is recommended by the American Psychiatric 
 
 
SR0119- 2 -LRB103 31105 LAW 57766 r

1Association (APA); and
  
 
2    WHEREAS, Clinical research has led to the availability of 
3two treatments for adults with TD by the U.S. Food and Drug 
4Administration; and
  
 
5    WHEREAS, The Legislature can raise awareness of Tardive

6Dyskinesia in the public and in the medical community; 
7therefore, be it
  
 
8    RESOLVED, BY THE SENATE OF THE ONE HUNDRED THIRD GENERAL 
9ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 1 
10through May 7, 2023 as Tardive Dyskinesia Awareness Week in 
11the State of Illinois; and be it further
  
 
12    RESOLVED, That we encourage the citizens of Illinois to

13become better informed about Tardive Dyskinesia.